{"schema_version":"1.0","type":"article","title":"諾華Entresto跌38%，心臟接班看Leqvio","url":"https://drugnews.com.tw/articles/2026-11-03-novartis-entresto-generic-leqvio-orion4-heart-bet.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-03-novartis-entresto-generic-leqvio-orion4-heart-bet.md","lang":"zh-Hant","date":"2026-11-03","publish_at":"2026-11-03T08:00:00+08:00","updated_at":"2026-11-03","category":"製藥巨頭系列","topic":"製藥巨頭系列","tags":["諾華 Novartis","Entresto 健安心","Leqvio 樂脂益","降膽固醇","Lp(a)"],"summary":"賣了十年的心衰竭藥王 Entresto，學名藥一來單季少賺 38%。諾華押的兩張接班牌九月一週內倒下，剩一年兩針的降膽固醇藥 Leqvio。我們的判斷是年底 ORION-4 會成功，因為它打的是已被證明過的靶點。","key_points":["ORION-4 是 Leqvio（inclisiran）的心血管結局試驗，預計收 15,000 人、治療約五年，諾華預計 2026 年第四季公布；Leqvio 2026 年第三季銷售 5.06 億美元、年增 64%。","諾華 2026 年 10 月 27 日公布第三季：心衰竭藥 Entresto 單季 11.65 億美元、固定匯率年減 38%，前九個月 36.51 億美元（去年同期 64.95 億）；美國學名藥自 2025 年 7 月 22 日上市。","諾華兩張接班牌在 2026 年 9 月一週內失敗：Lp(a) 藥 pelacarsen 的 8,323 人 HORIZON 三期 9 月 4 日未達主要終點、美國不送件；del-desiran 9 月 8 日 HARBOR 失敗，第三季認列 19 億美元減值。"],"facts":[{"claim":"Entresto 2026 年第三季淨銷售","value":1165,"unit":"百萬美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Entresto 2026 年第三季銷售年減（固定匯率）","value":"-38","unit":"%","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Entresto 2026 年前九個月淨銷售","value":3651,"unit":"百萬美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Entresto 2025 年前九個月淨銷售","value":6495,"unit":"百萬美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Entresto 2024 年全年淨銷售","value":7822,"unit":"百萬美元","as_of":"2025-01-31","source":"https://www.sec.gov/Archives/edgar/data/1114448/000137036825000008/a250131-99_2.pdf"},{"claim":"FDA 核准 Entresto 日期","value":"2015-07-07","unit":"日期","as_of":"2015-07-07","source":"https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda-reduce-risk-cardiovascular-death-and-heart-failure-hospitalization"},{"claim":"PARADIGM-HF 試驗人數","value":8442,"unit":"人","as_of":"2015-07-07","source":"https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda-reduce-risk-cardiovascular-death-and-heart-failure-hospitalization"},{"claim":"美國首個 Entresto 學名藥上市日（Novadoz／MSN）","value":"2025-07-22","unit":"日期","as_of":"2025-07-30","source":"https://business.optum.com/en/support/professionalrx-resources/newgeneric-entresto-073025.html"},{"claim":"諾華 2026 年第三季集團淨銷售","value":14.5,"unit":"十億美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Kisqali 2026 年第三季淨銷售","value":1821,"unit":"百萬美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Kisqali 2026 年前九個月淨銷售","value":5032,"unit":"百萬美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Cosentyx 2026 年第三季淨銷售","value":1857,"unit":"百萬美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Leqvio 2026 年第三季淨銷售","value":506,"unit":"百萬美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Leqvio 2026 年第三季銷售年增","value":64,"unit":"%","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"del-desiran 在研資產 2026 年第三季減值","value":1.9,"unit":"十億美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"del-desiran 減值後帳面價值","value":5.5,"unit":"十億美元","as_of":"2026-10-27","source":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"claim":"Lp(a)HORIZON 收案人數","value":8323,"unit":"人","as_of":"2026-09-04","source":"https://ir.ionis.com/news-releases/news-release-details/ionis-partner-novartis-announces-lpahorizon-phase-3-topline"},{"claim":"諾華收購 Avidity 股權價值","value":12,"unit":"十億美元","as_of":"2025-10-26","source":"https://www.sec.gov/Archives/edgar/data/1599901/000119312525250696/d25008dex991.htm"},{"claim":"Leqvio 降低 LDL 膽固醇幅度（最多，相對安慰劑）","value":52,"unit":"%","as_of":"2021-12-22","source":"https://www.sec.gov/Archives/edgar/data/1114448/000117184321008671/f6k_122221.htm"},{"claim":"ORION-4 預計收案人數","value":15000,"unit":"人","as_of":"2026-10-28","source":"https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/orion-4/"},{"claim":"FOURIER 試驗人數","value":27564,"unit":"人","as_of":"2017-03-17","source":"https://acc.org/Latest-in-Cardiology/Articles/2017/03/10/19/18/Fri-9am-FOURIER-Further-CV-Outcomes-Research-With-PCSK9-Inhibition-in-Elevated-Risk-Patients-acc-2017"},{"claim":"FOURIER 主要心血管事件相對降幅","value":15,"unit":"%","as_of":"2017-03-17","source":"https://acc.org/Latest-in-Cardiology/Articles/2017/03/10/19/18/Fri-9am-FOURIER-Further-CV-Outcomes-Research-With-PCSK9-Inhibition-in-Elevated-Risk-Patients-acc-2017"},{"claim":"Amgen olpasiran 結局試驗預計公布年","value":2028,"unit":"年","as_of":"2026-09-08","source":"https://www.biospace.com/drug-development/novartis-cholesterol-lowering-medicine-fails-phase-3-clouding-lpa-horizons"},{"claim":"禮來 lepodisiran 結局試驗預計公布年","value":2029,"unit":"年","as_of":"2026-09-08","source":"https://www.biospace.com/drug-development/novartis-cholesterol-lowering-medicine-fails-phase-3-clouding-lpa-horizons"},{"claim":"Leqvio 管理層高峰銷售指引（以上）","value":4,"unit":"十億美元","as_of":"2026-10-27","source":"https://www.investing.com/news/transcripts/earnings-call-transcript-novartis-beats-q3-2026-eps-forecast-lifts-profit-outlook-93CH-4975830"}],"sections":["01｜十年藥王，一個夏天就少了一半","02｜兩張接班牌，九月一週內倒下","03｜同樣是 RNA 藥，Leqvio 為什麼過得了這關","04｜開獎之後，Leqvio 能撐起多大的洞","參考資料"],"references":[{"title":"Novartis Q3 2026 interim financial report (Form 6-K","source":"Novartis／SEC","date":"2026-10-27","url":"https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000014/a261027-99_2.htm"},{"title":"Novartis Q3 2026 investor presentation","source":"Novartis","date":"2026-10-27","url":"https://www.novartis.com/sites/novartis_com/files/q3-2026-investor-presentation.pdf"},{"title":"Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy","source":"BioSpace","date":"2026-10-27","url":"https://www.biospace.com/business/novartis-faces-1-9b-hit-from-avidity-fail-but-maintains-confidence-in-12b-buy"},{"title":"Earnings call transcript: Novartis beats Q3 2026 EPS forecast, lifts profit outlook","source":"Investing.com","date":"2026-10-27","url":"https://www.investing.com/news/transcripts/earnings-call-transcript-novartis-beats-q3-2026-eps-forecast-lifts-profit-outlook-93CH-4975830"},{"title":"Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen","source":"Ionis Pharmaceuticals","date":"2026-09-04","url":"https://ir.ionis.com/news-releases/news-release-details/ionis-partner-novartis-announces-lpahorizon-phase-3-topline"},{"title":"Novartis' cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons","source":"BioSpace","date":"2026-09-08","url":"https://www.biospace.com/drug-development/novartis-cholesterol-lowering-medicine-fails-phase-3-clouding-lpa-horizons"},{"title":"Novartis RNA drug fails in DM1 study, setting back Avidity bet","source":"BioPharma Dive","date":"2026-09-08","url":"https://www.biopharmadive.com/news/novartis-rna-drug-failure-dm1-avidity-del-desiran/829778/"},{"title":"Novartis new heart failure medicine LCZ696, now called Entresto, approved by FDA","source":"Novartis","date":"2015-07-07","url":"https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda-reduce-risk-cardiovascular-death-and-heart-failure-hospitalization"},{"title":"New generic: Entresto","source":"Optum Rx","date":"2025-07-30","url":"https://business.optum.com/en/support/professionalrx-resources/newgeneric-entresto-073025.html"},{"title":"Novartis Q4 and full year 2024 financial results (Form 6-K","source":"Novartis／SEC","date":"2025-01-31","url":"https://www.sec.gov/Archives/edgar/data/1114448/000137036825000008/a250131-99_2.pdf"},{"title":"FDA approves Novartis Leqvio, first-in-class siRNA to lower cholesterol (Form 6-K","source":"Novartis／SEC","date":"2021-12-22","url":"https://www.sec.gov/Archives/edgar/data/1114448/000117184321008671/f6k_122221.htm"},{"title":"ORION-4 research summary","source":"NHS Health Research Authority","date":"2026-10-28","url":"https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/orion-4/"},{"title":"FOURIER: Evolocumab significantly reduces risk of cardiovascular events","source":"American College of Cardiology","date":"2017-03-17","url":"https://acc.org/Latest-in-Cardiology/Articles/2017/03/10/19/18/Fri-9am-FOURIER-Further-CV-Outcomes-Research-With-PCSK9-Inhibition-in-Elevated-Risk-Patients-acc-2017"},{"title":"Novartis to acquire Avidity Biosciences (Exhibit 99.1, Form 8-K","source":"Avidity Biosciences／SEC","date":"2025-10-26","url":"https://www.sec.gov/Archives/edgar/data/1599901/000119312525250696/d25008dex991.htm"},{"title":"明星心臟藥銷售減半，諾華的新藥接棒來得及嗎？","source":"藥時事","date":"2026-10-06","url":"https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation.html"}],"images":[],"cover_image":"https://drugnews.com.tw/assets/articles/novartis-entresto-generic-leqvio-orion4-heart-bet/default-brand.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-03）。諾華Entresto跌38%，心臟接班看Leqvio。https://drugnews.com.tw/articles/2026-11-03-novartis-entresto-generic-leqvio-orion4-heart-bet.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}